ranged from 2.4% on day 0 to 4.3% on day 4 and did not appear to be time-dependent. All of the differences for individual pairs of tubes were Ͻ10%, except on 2 days for one set of specimens, where the differences were 23% and 16%. These may have been attributable to inadequate mixing, because Dasgupta et al. found similar differences in inadequately mixed tubes. The average concentrations varied only slightly from day to day.
In the second experiment, 10 samples from 10 patients were stored at room temperature and analyzed at the same intervals as the previous experiment. Cyclosporine concentrations ranged from 151 to 662 g/L. Because of questions concerning mixing in the previous experiment, the mixing step was standardized at 10 min of rocking. These data are also shown in Table 1 . The mean concentrations for the glass tubes were not statistically different from the mean concentrations for the plastic tubes on any day (unpaired ttests). Two of the paired t-tests showed statistical significance. The average percentage difference between the glass and plastic tubes ranged from Ϫ1.0% to 2.7%. All of the differences for individual pairs of tubes were Ͻ10%, except on 1 day for one set of specimens from one patient, where the difference was 14%. Dasgupta et al. (3) considered differences of Ͻ10% acceptable. In addition, the Canadian Consensus Panel (4) considered an error of 30 g/L at a concentration of 300 g/L (10%) acceptable. Because the average of the differences from our study are well within these ranges, we consider the plastic tubes acceptable for collection of specimens for cyclosporine measurement. Furthermore, we found that cyclosporine concentrations are stable in plastic tubes over 7 days at 4°C or at room temperature.
The plastic collection tubes used in the first experiment were provided by Becton Dickinson Vacutainer Systems (Franklin Lakes, NJ). We thank Valerie Bush of Becton Dickinson for reviewing the data and analysis.
Steven M. Faynor * Randy Robinson West Virginia University Hospitals
Clinical Laboratories Morgantown, WV 26506 *Author for correspondence.
Response to a Report on False-Positive Results in a Methadone Enzyme Immunoassay
To the Editor: In a recent technical brief, Lichtenwalner et al. (1) described their observation of false-positive results, caused by verapamil, in an immunoassay for methadone (Diagnostic Reagents, Inc.). The reagents used in this investigation (lot nos. 5E059, 5M112, 6E083, and 6M174) were manufactured during 1995 and 1996, based on the lot numbers disclosed by the investigators. We would like to report that such false-positive results have been corrected since June 1997 with the incorporation of a new monoclonal anti-methadone antibody.
It is well understood that the specificity of immunological assays may be compromised because of crossreactivity with other structurally similar compounds. However, with the availability of monoclonal antibody technology (2), one can improve the specificity of the assay by prescreening the desired monoclonal antibody against a panel of undesired cross-reactants. The challenge is always to come up with an optimal list of undesired drugs that should be investigated and to keep up with new drugs that are being continually introduced.
Verapamil, a calcium channelblocking agent used for the treatment of hypertension and arrhyth- mias, was not included in the original screening panel for the selection of a monoclonal anti-methadone antibody. With the feedback from users such as Lichtenwalner (Drug-Scan, Inc.), we confirmed that verapamil and its metabolites did cause false-positive responses in our methadone enzyme immunoassay (EIA). Verapamil was then included in our immediate selection effort of a new monoclonal anti-methadone antibody. We are happy to report that a new antibody without the interference by verapamil and its metabolites has been identified and used in the formulation of the methadone EIA assay since June 1997. With the methadone reagents manufactured before June 1997, verapamil parent drug at a concentration of 15 mg/L can give a positive response in the assay, whereas verapamil as high as 1 g/L will still give a negative response in the subsequent lots of reagent.
We agree with Lichtenwalner et al. (1) that immunological urine drug screen assays provide only a preliminary analytical result and should be used for excluding the presence of a particular drug in the sample. A more specific alternative analytical method such as HPLC or gas chromatography-mass spectrometry should be used for confirmation of positive results. We would like to thank our users who have constantly provided us with valuable feedback to assist us in improving the test devices. 
Yuh-geng Tsay

Three of the authors of the Technical Brief cited above respond:
To the Editor:
We are pleased to find that the interferences mentioned in our publication (1) have been eliminated. Utilization of monoclonal antibodies has substantially increased the specificity of immunoassays in recent years. The fact that a 60-fold increase in the amount of verapamil still shows no cross-reactivity to the newly formulated methadone antibody should completely eliminate any further false-positive responses caused by verapamil.
Mark R. Lichtenwalner
Thomas 
Diagnostic Criteria for Diabetes Mellitus
To the Editor: In his editorial article (1), Dr. Sacks welcomes the new guidelines for diagnosis of diabetes published recently by the American Diabetes Association (ADA) (2) . Replacement of the oral glucose tolerance test (OGTT) by measurement of fasting plasma glucose (FPG) on more than one occasion certainly simplifies the diagnostic procedure, and the chosen FPG cutoff of Ն7.0 mmol/L (Ն126 mg/dL) appears to be almost as sensitive for diabetes detection as the OGTT 2-h plasma glucose (2hPG). Unfortunately, the situation is not quite as simple as that.
We recently conducted a survey of 401 nonpregnant subjects having OGTT because of suspected diabetes mellitus (3) . The OGTT was performed according to WHO protocol and interpreted on the basis of the 2hPG value. The prevalence of diabetes in this population according to the results of the OGTT was 44.4%, compared with 41.4% by the ADA FPG criterion. This is in line with the ADA's data on the different sensitivities of the two tests and suggests that they are giving approximately the same answers. However, when we compared results by the two methods for individual patients, the agreement was not always so good. Of 178 patients positive for diabetes by 2hPG, only 139 were positive by the ADA FPG criterion, which means the latter gave 39 (22%) false negatives if the OGTT 2hPG is regarded as the reference method. This discrepancy was not immediately apparent in the prevalence figures because 27 other subjects were falsely positive by the ADA criterion, and these partially balanced the false negatives. In its overall view of the situation, the ADA seems to have omitted considering in any detail the possibility of a substantial number of individual discrepancies within the population. Furthermore, subjects whose FPG is lower than 6.1 mmol/L (110 mg/dL) are regarded by the ADA criteria as normal; available evidence, however, suggests that an appreciable proportion of diabetics have FPG below this (4, 5) , and our recent survey confirms it. Eighteen out of 178 subjects with a diabetic OGTT 2hPG had FPG below 6.1 mmol/L (110 mg/dL).
Owing to the change from the OGTT to FPG, the term impaired glucose tolerance (IGT) has had to be replaced by impaired fasting glucose (IFG), the latter being FPG in the range 6.1-6.9 mmol/L (110 -125 mg/ dL) inclusive. In our survey, 94 subjects fell into the IGT category, but only 27 of these met the criteria for IFG. Therefore, the two categories cannot really be regarded as equivalent.
Similar discrepancies between the two methods of classification were recently reported by Harris et al. (6) .
In an assessment of the prevalence of undiagnosed diabetes in a population, the ADA criteria detected 4.4% compared with 6.4% by WHO crite-
